---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-104104"
form_type: "8-K"
ticker: "OKUR"
cik: "0001637715"
company_name: "OnKure Therapeutics, Inc."
filed_at: "2026-03-12T23:59:59+00:00"
generated_at: "2026-05-15T13:33:28.026027+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# OnKure Therapeutics Q4 2025 net loss narrows to $13.5M; expects March data readouts

## Summary
- Net loss of $13.5M ($0.99/sh) for Q4 2025 vs $17.4M ($1.37/sh) in Q4 2024; expenses decreased.
- Cash and equivalents $59.1M as of Dec 31, 2025.
- PIKture-01 trial (OKI-219) data expected March 2026 across mono, combo, and triplet arms.
- Next-gen PI3Kα pan-mutant inhibitor candidate for HR+ breast cancer to be announced March 2026.
- R&D expenses $10.7M vs $14.4M YoY; G&A $3.4M vs $4.3M.

## SEC filing metadata
- accession: 0001193125-26-104104
- form_type: 8-K
- ticker: OKUR
- cik: 0001637715
- company_name: OnKure Therapeutics, Inc.
- filed_at: 2026-03-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1637715/000119312526104104/0001193125-26-104104-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1637715/000119312526104104/okur-20260312.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-104104
- JSON: https://secwatch.observer/filing/0001193125-26-104104.json
- Plain text: https://secwatch.observer/filing/0001193125-26-104104.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.